Compare Teucrium Soybean Fund (SOYB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teucrium Soybean Fund vs State Street SPDR S&P Biotech ETF — how do they compare? Teucrium Soybean Fund trades at $27.55 (market cap $43.52M), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 232.3× Teucrium Soybean Fund's market cap, and Teucrium Soybean Fund is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Teucrium Soybean Fund for 23 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SOYB | XBI | |
|---|---|---|
Market Cap | $43.52M | $10.11B |
Volume | 32,585 | 12,903,266 |
Sector | Commodities - Metals/Agriculture | Broad Market / Factor |
52-Week High | $28.14 | $169.55 |
52-Week Low | $21.55 | $104.99 |
Typical Hold Time | 23 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOYB trades at $27.57, down slightly by 0.07% today, with a bullish technical signal driven by strong moving average alignment. Recent news highlights potential catalysts from U.S.-China trade talks and agricultural commodity trends. Key support and resistance are tightly clustered around $27 and $28, indicating a consolidation phase.
The outlook is cautiously optimistic due to positive technical momentum and geopolitical developments, but fundamental data is unavailable, limiting valuation clarity. Risks include trade negotiation outcomes and broader commodity market volatility, requiring careful monitoring of upcoming earnings and guidance for a complete investment picture.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
